{
  "links": "https://www.ycombinator.com/companies/abalone-bio",
  "name": "Abalone Bio",
  "headline": "We discover antibody drugs others can't",
  "batch": "W20",
  "description": "Abalone Bio developed a technology to find antibody drugs that activate and modulate cell surface receptors, the “antennae” on cells that help convert chemical signals into cellular responses, like growth. Antibodies are a growing class of drugs that have tremendous safety and efficacy advantages over small molecules; 7 of the top 10 selling drugs are antibodies, earning an average of $7B in revenue. However, antibodies- especially ones that activate and modulate cell surface receptors- are hard to find. Abalone Bio expands the playing field for antibody therapeutics and enables us to previously access treatments for untreated diseases.\r\n\nWe have already discovered a novel antibody that activates a non-opioid receptor that produces analgesia. We are developing this antibody into a treatment for neuropathic pain – a medical condition that currently is treated with drugs like addictive opiates. The same molecule is also a potential treatment for inflammatory and fibrotic diseases, all 1B+ markets.",
  "activity_status": "Active",
  "website": "https://www.abalonebio.com",
  "founded_date": 2018.0,
  "team_size": 12.0,
  "location": "Emeryville, CA",
  "group_partner": null,
  "group_partner_yc": null,
  "company_linkedin": null,
  "company_twitter": null,
  "tags": "industry:machine-learning; industry:synthetic-biology; industry:drug-discovery; location:san-francisco-bay-area",
  "founders": [
    {
      "name": "Richard Yu, Founder",
      "description": "Rich has been in or around biotech startups since 2008, when co-founded GPB, an algae biofuel startup. He was also Scientific and Operations Director at MBC Biolabs, the leading biotech incubator in SF, and Principal at Mission Bay Capital, a life science VC fund. Prior, he was an investigator at The Molecular Sciences Institute studying how cells process information.\nPhD (2000) Molecular Biophysics and Biochemistry, Yale\nBA (1993) Biophysics and Computer Science (AI and Graphics), UC Berkeley",
      "linkedin": "https://www.linkedin.com/in/richard-c-yu/"
    },
    {
      "name": "Gustavo Pesce",
      "description": null,
      "linkedin": "https://www.linkedin.com/in/gustavopesce/"
    }
  ],
  "status": true,
  "markdown": "raw_markdown='[Home](https://www.abalonebio.com/</>)[Platform](https://www.abalonebio.com/</platform>)[Pipeline](https://www.abalonebio.com/</pipeline>)[Partnerships](https://www.abalonebio.com/</partnerships>)[Careers](https://www.abalonebio.com/</careers>)[News](https://www.abalonebio.com/</media>)[![LinkedIn](https://cdn.prod.website-files.com/670d5e01fc14a207c7bb0b53/671218308bbe2388db326d78_icon-linkedin.svg)LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n[![Abalone Bio](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a08_iconlogo-default.svg)![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a07_iconlogo-hover.svg)![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a06_iconlogo-click.svg)![Abalone Bio](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a04_wordmark.svg)](https://www.abalonebio.com/</>)[Home](https://www.abalonebio.com/</>)[Platform](https://www.abalonebio.com/</platform>)[Pipeline](https://www.abalonebio.com/</pipeline>)[Partnerships](https://www.abalonebio.com/</partnerships>)[Careers](https://www.abalonebio.com/</careers>)[News](https://www.abalonebio.com/</media>)[![LinkedIn](https://cdn.prod.website-files.com/670d5e01fc14a207c7bb0b53/671218308bbe2388db326d78_icon-linkedin.svg)LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a01_navbar-menu.svg)\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a00_navbar-close.svg)\\n# Unleashing therapeutic biology\\nThe Challenge\\n## Creating antibody activators for key disease targets\\nTarget Challenge\\n### Key targets lack drugs\\nMillions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets. \\nDrug Challenge\\n### Existing drugs lack specificity\\nSmall molecules or peptides often have off-target interactions, resulting in intolerable side effects.\\nAntibody Challenge\\n### Antibodies are specific but lack activity\\nAntibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.\\nTargets Challenge\\n### Key targets lack drugs\\nMillions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets. \\nDrugs Challenge\\n### Existing drugs lack specifity\\nSmall molecules or peptides often have off-target interactions, resulting in intolerable side effects.\\nAntibodies Challenge\\n### Antibodies are specific but lack activity\\nAntibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.\\n[](https://www.abalonebio.com/<#>)[](https://www.abalonebio.com/<#>)\\nSwipe\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f6_Arrow.svg)\\n![Proteins over membrane](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5d_proteins-and-membrane.svg)![Stylized light blue letter \"W\" with whimsical curls on a black background.](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f3e06425009c8b6a0779a_Graphic-01.svg)![Antibody](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5f_antibody-blues.svg)![Protein](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5e_Group%2032.svg)![Blue proteins](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f412f2e2556332b634987_Graphic-01go.svg)\\nHow are we different?\\n## We create target-activating antibodies that unlock key challenging disease targets\\nFAST\\nWe have developed our Functional Antibody Selection Technology (FAST) platform to rapidly create difficult-to-discover antibody activators for challenging and promising target classes. We focus first on key G-protein coupled receptors (GPCRs), which play a role in regulating nearly every biological area.\\n## What makes us different? \\n### We tackle GPCRs, the hardest target class for antibodies\\nUnlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.\\n![Kidney](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a34_kidney.svg)\\n![Brain](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a35_brain.svg)\\n![GPCR](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a37_GPCR_icon.svg)\\n![Heart](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a36_hearth.svg)\\n![Stomach](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a33_stomach.svg)\\n![100 million](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a39_100-million.svg)\\n### We measure function not just binding: 100M antibodies at once, 100X more than others\\nWe biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.\\n### We have enabled AI to predict activating antibodies, a first in the field\\nWe don’t only discover rare activators. Our large, proprietary activity datasets pave the path to AI-guided antibody design.\\n![Protein and antibody](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a60_center-ai.svg)![Computer](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a61_Isolation-Mode.svg)\\nOnly\\n![Antibody](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9c19d333eaa348215364_Group%20272.svg)\\n6 GPCR\\nhave had antibody activators discovered for them.\\n![Row of 3D grey and blue cylindrical shapes representing data or sound waves.](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9b98279c554824eb30f9_Group%20275.svg)\\nAbalone Bio\\nhas unlocked\\n![Antibody](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9c600980afe10ab34ed8_Group%20269.svg)\\n2 of them\\n### It\\'s not just an idea. We\\'ve already done it twice\\nWe’ve built and derisked the platform and are currently creating activating antibodies for our internal pipeline and our partners.\\n### We tackle GPCRs, the hardest target class for antibodies\\nUnlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.\\n### We measure function not just binding: 100M antibodies at once, 100X more than others\\nWe biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.\\n### We have enabled AI predict active antibodies, a first in the field\\nWe haven’t just discovered rare activators. Using our large proprietary activity datasets , we have compiled large-scale activity data that paves the path to design.\\n### We have created agonists for our internal programs and pharma partners\\nOur system works: we have discovered activators for 2 GPCRs - only 4 others have even been done before us.\\n## Our leadership team\\n### Discovering the next generation of antibody drugs\\nRichard Yu, PhD\\nCEO and Co-Founder\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nToshi Takeuchi, PhD\\nCSO\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nLauren Schwimmer\\nVP of Preclinical Development\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nSameer Soi\\nVP of data science & AI\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nRichard Yu, PhD\\nCEO and Co-Founder\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nToshi Takeuchi, PhD\\nCSO\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nLauren Schwimmer\\nVP of Preclinical Development\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\nSameer Soi\\nVP of data science & AI\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\n[](https://www.abalonebio.com/<#>)[](https://www.abalonebio.com/<#>)\\nSwipe\\n![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f6_Arrow.svg)\\n## Overview\\n### [PlatformWe have harnessed nature\\'s \"survival of the fittest\" to test hundreds of millions of antibodies for activity, not just binding, in parallel. ![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)](https://www.abalonebio.com/</platform>)### [PipelineWe are focused on diseases impacting millions of lives that can uniquely be addressed with target-activating antibodies.![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)](https://www.abalonebio.com/</pipeline>)### [PartnershipsWe are working with top drug companies to bring them target-activating antibodies for their key targets. Learn more about Abalone Bio.![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)](https://www.abalonebio.com/</partnerships>)### [CareersWe believe if you have the right people, then with a meaningful goal, hard work, and a bit of luck, good things will inevitably emerge. We are hiring!![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)](https://www.abalonebio.com/</careers>)\\nSameer Soi\\nVP of data science & AI\\nData and AI Platform\\nWith experiences spanning health tech, synthetic biology, and drug discovery, Dr. Soi has spearheaded initiatives leveraging data and machine learning to drive impact for patients. \\n\\u200d\\nAt Atomwise, as Director of Drug Discovery Data Science, he led the development of uncertainty quantification methods for deep learning models of small molecule binding as well as tools for evaluating and improving similarity-based searches for hit-to-lead generation. \\n\\u200d\\nAt Zymergen, he managed the productionization of statistical and machine learning models that supported the company’s portfolio of high- throughput screening projects. Before that, at Grand Rounds (now Included Health) he engineered a platform enabling the scaling of machine learning for clinical outcomes models across indications for which he received a patent.\\nPh.D., Genomics & Computational Biology, 2015, University of Pennsylvania\\nFavorite Outside Work or Activity\\nEnjoying visiting museums with his toddler and wine country without his toddler.\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\nPlatform Technology Development\\nAntibody Discovery\\nMonica has a deep background in early discovery and platform development.\\u200d\\nAt Achaogen, she led the development of a microfluidic B-cell capture and screening platform, in addition to her efforts in target development and characterization.\\u200d\\nAt Zymergen, she was project and portfolio leads for multiple teams to develop and scale cellular engineering technologies.\\nPh.D., Biochemistry and Molecular Biology, 2005, University of California, San Francisco\\nFavorite Outside Work or Activity\\nHiking and biking\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nLauren Schwimmer\\nVP of Preclinical Development\\nAntibody Development\\nLauren brings a wealth of antibody and immuno-oncology drug development experience to Abalone Bio.\\u200d\\nAt Xoma and Distributed Bio, she was behind the development of two of the most well-regarded antibody libraries used for antibody drug discovery, and she managed multiple antibody drug discovery and preclinical drug development teams.\\u200d\\nAt QLSF, she directed three pre-clinical stage bispecific antibody drug development programs for immuno-oncology.\\nPh.D., Biochemistry, 2005 Georgia Institute of Technology\\nFavorite Outside Work or Activity\\nDancing, reading, and coaching robotics\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nToshi Takeuchi, PhD\\nCSO\\nHead of R&D\\nAcademic and Industry Partnerships\\nToshi brings over 20 years of industrial experience and expertise in antibody expression and engineering, therapeutic discovery and development, and project and departmental leadership to Abalone Bio.\\u200d\\nPrior to joining Abalone Bio, Toshi worked at companies ranging from small startups (Bioren, acquired by Pfizer) to large multinational companies (Bayer). As VP of Discovery Research at XOMA Corporation, he was responsible for selection, engineering and characterization of multiple clinically developed antibodies. Most recently, as VP of Discovery Research at Second Genome, he helped develop therapeutics derived from the human microbiome.\\nPh.D., Chemistry 1996California Institute of Technology\\nFavorite Outside Work or Activity\\nCycling, playing violin, gardening, meditating and spending time with family (when they tolerate him)\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nRichard Yu, PhD\\nCEO and Co-Founder\\nBoard Director\\nHead of Operations\\nBusiness Development\\nRichard has been in and around startups since 2008, on both sides of the lease and term sheet, as founder, incubator manager, and venture capital principal.\\u200d\\nHis path to co-founding Abalone Bio started at UC Berkeley in Biophysics and Computer science, and wound its way through protein engineering, structural biology, and then systems biology and synthetic biology at the Molecular Sciences Institute, where he met co-founder Gustavo Pesce.\\u200d\\nAbalone Bio grew out of an “a-ha!” moment shared with Gustavo defining a technology that uniquely combines their skillsets and experiences to meet a long-standing therapeutic need- safe and effective drugs for promising yet difficult to drug targets.\\nPh.D., Mol. Biochemistry & Biophysics, 2000 Yale University\\nFavorite Outside Work or Activity\\nMaking or fixing things around the house or lab, rock climbing, motorcycling, tea and coffee obsessing\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nNewsroom\\n## Press inquires\\nExcited to share our story! Connect with us at the email below for media inquiries.\\npress@abalonebio.com![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg)\\n[![Home page](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899d1_iconlogo-footer.svg)](https://www.abalonebio.com/</>)\\nAbalone Bio\\n1250, 45st. Ste 520,Emeryville, CA, USA, 94608\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n[Platform](https://www.abalonebio.com/</platform>)[Pipeline](https://www.abalonebio.com/</pipeline>)[Partnerships](https://www.abalonebio.com/</partnerships>)[Careers](https://www.abalonebio.com/</careers>)\\n[![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg)LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n[![A product by Codon65](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a59_sign-default.svg)![A product by Codon65](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a58_sign-hover.svg)](https://www.abalonebio.com/<https:/www.codon65.com/>)\\nAbalone Bio © All rights reserved.\\n© 2025\\n' markdown_with_citations='Home⟨1⟩Platform⟨2⟩Pipeline⟨3⟩Partnerships⟨4⟩Careers⟨5⟩News⟨6⟩![LinkedIn⟨7⟩LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n![Abalone Bio⟨8⟩![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a07_iconlogo-hover.svg)![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a06_iconlogo-click.svg)![Abalone Bio⟨9⟩]](https://www.abalonebio.com/</>)Home⟨1⟩Platform⟨2⟩Pipeline⟨3⟩Partnerships⟨4⟩Careers⟨5⟩News⟨6⟩![LinkedIn⟨7⟩LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a01_navbar-menu.svg)\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a00_navbar-close.svg)\\n# Unleashing therapeutic biology\\nThe Challenge\\n## Creating antibody activators for key disease targets\\nTarget Challenge\\n### Key targets lack drugs\\nMillions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets. \\nDrug Challenge\\n### Existing drugs lack specificity\\nSmall molecules or peptides often have off-target interactions, resulting in intolerable side effects.\\nAntibody Challenge\\n### Antibodies are specific but lack activity\\nAntibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.\\nTargets Challenge\\n### Key targets lack drugs\\nMillions of patients remain untreated because drug discovery has failed to deliver therapeutics for many key disease targets. \\nDrugs Challenge\\n### Existing drugs lack specifity\\nSmall molecules or peptides often have off-target interactions, resulting in intolerable side effects.\\nAntibodies Challenge\\n### Antibodies are specific but lack activity\\nAntibodies can recognize their targets with exquisite specificity. However, it has been a very difficult task to find activators.\\n[](https://www.abalonebio.com/<#>)[](https://www.abalonebio.com/<#>)\\nSwipe\\n![Arrow right⟨10⟩]\\n![Proteins over membrane⟨11⟩]![Stylized light blue letter \"W\" with whimsical curls on a black background.⟨12⟩]![Antibody⟨13⟩]![Protein⟨14⟩]![Blue proteins⟨15⟩]\\nHow are we different?\\n## We create target-activating antibodies that unlock key challenging disease targets\\nFAST\\nWe have developed our Functional Antibody Selection Technology (FAST) platform to rapidly create difficult-to-discover antibody activators for challenging and promising target classes. We focus first on key G-protein coupled receptors (GPCRs), which play a role in regulating nearly every biological area.\\n## What makes us different? \\n### We tackle GPCRs, the hardest target class for antibodies\\nUnlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.\\n![Kidney⟨16⟩]\\n![Brain⟨17⟩]\\n![GPCR⟨18⟩]\\n![Heart⟨19⟩]\\n![Stomach⟨20⟩]\\n![100 million⟨21⟩]\\n### We measure function not just binding: 100M antibodies at once, 100X more than others\\nWe biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.\\n### We have enabled AI to predict activating antibodies, a first in the field\\nWe don’t only discover rare activators. Our large, proprietary activity datasets pave the path to AI-guided antibody design.\\n![Protein and antibody⟨22⟩]![Computer⟨23⟩]\\nOnly\\n![Antibody⟨24⟩]\\n6 GPCR\\nhave had antibody activators discovered for them.\\n![Row of 3D grey and blue cylindrical shapes representing data or sound waves.⟨25⟩]\\nAbalone Bio\\nhas unlocked\\n![Antibody⟨26⟩]\\n2 of them\\n### It\\'s not just an idea. We\\'ve already done it twice\\nWe’ve built and derisked the platform and are currently creating activating antibodies for our internal pipeline and our partners.\\n### We tackle GPCRs, the hardest target class for antibodies\\nUnlike other target classes, which can be activated through dimerization or clustering, GPCRs require precise adjustments to their protein structures to activate or modulate them.\\n### We measure function not just binding: 100M antibodies at once, 100X more than others\\nWe biologically measure individual antibodies for activity in a massively parallel fashion with our engineered yeast cells that link cell survival to antibody functional against a target.\\n### We have enabled AI predict active antibodies, a first in the field\\nWe haven’t just discovered rare activators. Using our large proprietary activity datasets , we have compiled large-scale activity data that paves the path to design.\\n### We have created agonists for our internal programs and pharma partners\\nOur system works: we have discovered activators for 2 GPCRs - only 4 others have even been done before us.\\n## Our leadership team\\n### Discovering the next generation of antibody drugs\\nRichard Yu, PhD\\nCEO and Co-Founder\\n![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\nToshi Takeuchi, PhD\\nCSO\\n![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\n![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\nLauren Schwimmer\\nVP of Preclinical Development\\n![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\nSameer Soi\\nVP of data science & AI\\n![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\nRichard Yu, PhD\\nCEO and Co-Founder\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right⟨28⟩]\\nToshi Takeuchi, PhD\\nCSO\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right⟨28⟩]\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right⟨28⟩]\\nLauren Schwimmer\\nVP of Preclinical Development\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right⟨28⟩]\\nSameer Soi\\nVP of data science & AI\\n![](https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg)![Arrow right⟨28⟩]\\n[](https://www.abalonebio.com/<#>)[](https://www.abalonebio.com/<#>)\\nSwipe\\n![Arrow right⟨10⟩]\\n## Overview\\n### PlatformWe have harnessed nature\\'s \"survival of the fittest\" to test hundreds of millions of antibodies for activity, not just binding, in parallel. ![⟨27⟩![Arrow right⟨28⟩]](https://www.abalonebio.com/</platform>)### PipelineWe are focused on diseases impacting millions of lives that can uniquely be addressed with target-activating antibodies.![Arrow right⟨27⟩![Arrow right⟨28⟩]](https://www.abalonebio.com/</pipeline>)### PartnershipsWe are working with top drug companies to bring them target-activating antibodies for their key targets. Learn more about Abalone Bio.![Arrow right⟨27⟩![Arrow right⟨28⟩]](https://www.abalonebio.com/</partnerships>)### CareersWe believe if you have the right people, then with a meaningful goal, hard work, and a bit of luck, good things will inevitably emerge. We are hiring!![Arrow right⟨27⟩![Arrow right⟨28⟩]](https://www.abalonebio.com/</careers>)\\nSameer Soi\\nVP of data science & AI\\nData and AI Platform\\nWith experiences spanning health tech, synthetic biology, and drug discovery, Dr. Soi has spearheaded initiatives leveraging data and machine learning to drive impact for patients. \\n\\u200d\\nAt Atomwise, as Director of Drug Discovery Data Science, he led the development of uncertainty quantification methods for deep learning models of small molecule binding as well as tools for evaluating and improving similarity-based searches for hit-to-lead generation. \\n\\u200d\\nAt Zymergen, he managed the productionization of statistical and machine learning models that supported the company’s portfolio of high- throughput screening projects. Before that, at Grand Rounds (now Included Health) he engineered a platform enabling the scaling of machine learning for clinical outcomes models across indications for which he received a patent.\\nPh.D., Genomics & Computational Biology, 2015, University of Pennsylvania\\nFavorite Outside Work or Activity\\nEnjoying visiting museums with his toddler and wine country without his toddler.\\n![⟨29⟩LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nMonica Schwartz, PhD\\nVP of Antibody Discovery\\nPlatform Technology Development\\nAntibody Discovery\\nMonica has a deep background in early discovery and platform development.\\u200d\\nAt Achaogen, she led the development of a microfluidic B-cell capture and screening platform, in addition to her efforts in target development and characterization.\\u200d\\nAt Zymergen, she was project and portfolio leads for multiple teams to develop and scale cellular engineering technologies.\\nPh.D., Biochemistry and Molecular Biology, 2005, University of California, San Francisco\\nFavorite Outside Work or Activity\\nHiking and biking\\n![⟨29⟩LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nLauren Schwimmer\\nVP of Preclinical Development\\nAntibody Development\\nLauren brings a wealth of antibody and immuno-oncology drug development experience to Abalone Bio.\\u200d\\nAt Xoma and Distributed Bio, she was behind the development of two of the most well-regarded antibody libraries used for antibody drug discovery, and she managed multiple antibody drug discovery and preclinical drug development teams.\\u200d\\nAt QLSF, she directed three pre-clinical stage bispecific antibody drug development programs for immuno-oncology.\\nPh.D., Biochemistry, 2005 Georgia Institute of Technology\\nFavorite Outside Work or Activity\\nDancing, reading, and coaching robotics\\n![⟨29⟩LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nToshi Takeuchi, PhD\\nCSO\\nHead of R&D\\nAcademic and Industry Partnerships\\nToshi brings over 20 years of industrial experience and expertise in antibody expression and engineering, therapeutic discovery and development, and project and departmental leadership to Abalone Bio.\\u200d\\nPrior to joining Abalone Bio, Toshi worked at companies ranging from small startups (Bioren, acquired by Pfizer) to large multinational companies (Bayer). As VP of Discovery Research at XOMA Corporation, he was responsible for selection, engineering and characterization of multiple clinically developed antibodies. Most recently, as VP of Discovery Research at Second Genome, he helped develop therapeutics derived from the human microbiome.\\nPh.D., Chemistry 1996California Institute of Technology\\nFavorite Outside Work or Activity\\nCycling, playing violin, gardening, meditating and spending time with family (when they tolerate him)\\n![⟨29⟩LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nRichard Yu, PhD\\nCEO and Co-Founder\\nBoard Director\\nHead of Operations\\nBusiness Development\\nRichard has been in and around startups since 2008, on both sides of the lease and term sheet, as founder, incubator manager, and venture capital principal.\\u200d\\nHis path to co-founding Abalone Bio started at UC Berkeley in Biophysics and Computer science, and wound its way through protein engineering, structural biology, and then systems biology and synthetic biology at the Molecular Sciences Institute, where he met co-founder Gustavo Pesce.\\u200d\\nAbalone Bio grew out of an “a-ha!” moment shared with Gustavo defining a technology that uniquely combines their skillsets and experiences to meet a long-standing therapeutic need- safe and effective drugs for promising yet difficult to drug targets.\\nPh.D., Mol. Biochemistry & Biophysics, 2000 Yale University\\nFavorite Outside Work or Activity\\nMaking or fixing things around the house or lab, rock climbing, motorcycling, tea and coffee obsessing\\n![⟨29⟩LinkedIn ](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nNewsroom\\n## Press inquires\\nExcited to share our story! Connect with us at the email below for media inquiries.\\npress@abalonebio.com![Arrow right⟨27⟩]![Arrow right⟨28⟩]\\n![Home page⟨30⟩](https://www.abalonebio.com/</>)\\nAbalone Bio\\n1250, 45st. Ste 520,Emeryville, CA, USA, 94608\\n![⟨29⟩LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\nPlatform⟨2⟩Pipeline⟨3⟩Partnerships⟨4⟩Careers⟨5⟩\\n![⟨29⟩LinkedIn](https://www.abalonebio.com/<https:/www.linkedin.com/company/abalone-bio-inc/>)\\n![A product by Codon65⟨31⟩![A product by Codon65⟨32⟩]](https://www.abalonebio.com/<https:/www.codon65.com/>)\\nAbalone Bio © All rights reserved.\\n© 2025\\n' references_markdown='\\n\\n## References\\n\\n⟨1⟩ https://www.abalonebio.com/</>: Home\\n⟨2⟩ https://www.abalonebio.com/</platform>: Platform\\n⟨3⟩ https://www.abalonebio.com/</pipeline>: Pipeline\\n⟨4⟩ https://www.abalonebio.com/</partnerships>: Partnerships\\n⟨5⟩ https://www.abalonebio.com/</careers>: Careers\\n⟨6⟩ https://www.abalonebio.com/</media>: News\\n⟨7⟩ https://cdn.prod.website-files.com/670d5e01fc14a207c7bb0b53/671218308bbe2388db326d78_icon-linkedin.svg: ![LinkedIn\\n⟨8⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a08_iconlogo-default.svg: ![Abalone Bio\\n⟨9⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a04_wordmark.svg: Abalone Bio\\n⟨10⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f6_Arrow.svg: Arrow right\\n⟨11⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5d_proteins-and-membrane.svg: Proteins over membrane\\n⟨12⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f3e06425009c8b6a0779a_Graphic-01.svg: Stylized light blue letter \"W\" with whimsical curls on a black background.\\n⟨13⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5f_antibody-blues.svg: Antibody\\n⟨14⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a5e_Group%2032.svg: Protein\\n⟨15⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f412f2e2556332b634987_Graphic-01go.svg: Blue proteins\\n⟨16⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a34_kidney.svg: Kidney\\n⟨17⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a35_brain.svg: Brain\\n⟨18⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a37_GPCR_icon.svg: GPCR\\n⟨19⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a36_hearth.svg: Heart\\n⟨20⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a33_stomach.svg: Stomach\\n⟨21⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a39_100-million.svg: 100 million\\n⟨22⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a60_center-ai.svg: Protein and antibody\\n⟨23⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a61_Isolation-Mode.svg: Computer\\n⟨24⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9c19d333eaa348215364_Group%20272.svg: Antibody\\n⟨25⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9b98279c554824eb30f9_Group%20275.svg: Row of 3D grey and blue cylindrical shapes representing data or sound waves.\\n⟨26⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673f9c600980afe10ab34ed8_Group%20269.svg: Antibody\\n⟨27⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899e4_arrow-right.svg: Arrow right\\n⟨28⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899f5_arrow-right-hover.svg: Arrow right\\n⟨29⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899cd_icon-linkedin.svg: ![\\n⟨30⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f899d1_iconlogo-footer.svg: ![Home page\\n⟨31⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a59_sign-default.svg: ![A product by Codon65\\n⟨32⟩ https://cdn.prod.website-files.com/673e4ec5b5b3505435f8999c/673e4ec5b5b3505435f89a58_sign-hover.svg: A product by Codon65\\n' fit_markdown='' fit_html=''",
  "generated_description": "### Overview of Abalone Bio\n\n**Mission:** Abalone Bio is on a quest to uncover antibody drugs that others have overlooked. They aim to revolutionize how we treat diseases by focusing on the challenges inherent in accessing hard-to-target biological pathways.\n\n**Founded:** 2018, Abalone Bio emerged from innovative thought, sitting comfortably in the esteemed Y Combinator Batch W20.\n\n**Location:** Based in Emeryville, CA, a hub for biotech and innovation in the San Francisco Bay Area.\n\n**Team:** A nimble team of 12 experts, each bringing deep knowledge from various fields like machine learning, synthetic biology, and drug discovery. They also have support from their Group Partner, Nan.\n\n### The Challenge\n\nAntibodies, the backbone of modern therapeutics, are incredibly specific but can be hard to find, especially those that activate and modulate cell surface receptors—like switches that translate external signals into internal actions. The result? Many promising drug targets remain untreated, leaving millions of patients without effective therapies.\n\n### The Solution\n\nEnter Abalone Bio's **Functional Antibody Selection Technology (FAST)**, a platform designed to quickly generate antibody activators for notoriously difficult targets, specifically focusing on G-protein coupled receptors (GPCRs). The significance of this approach is immense as GPCRs regulate a vast array of biological responses.\n\n1. **Massive Parallelism:** Abalone Bio’s technology allows the examination of 100 million antibodies simultaneously. This scale is about 100 times more than what traditional methods can achieve. In essence, they measure the activity of potential antibodies, not just their ability to bind.\n\n2. **AI Integration:** They've integrated artificial intelligence into the process to predict which antibodies will be effective, a pioneering move within the industry.\n\n3. **Real-World Impact:** They are currently developing a novel antibody designed to treat neuropathic pain, among other conditions that traditional treatments often fail to address. Their discoveries also open up options for tackling inflammatory and fibrotic diseases—each representing billion-dollar markets.\n\n### The Leadership Team\n\n- **Richard Yu, PhD** - CEO and Co-Founder: A veteran in the startup realm with a background in biophysics and computer science.\n- **Toshi Takeuchi, PhD** - CSO: With over 20 years of industry expertise, Toshi drives R&D efforts and academic partnerships.\n- **Monica Schwartz, PhD** - VP of Antibody Discovery: Spearheads early discovery efforts and platform technology development.\n- **Lauren Schwimmer** - VP of Preclinical Development: A seasoned developer responsible for numerous successful antibody drug programs.\n- **Sameer Soi** - VP of Data Science & AI: Focuses on leveraging data and machine learning to optimize the drug discovery process.\n\n### Conclusion\n\nAbalone Bio isn’t just about creating drugs; it's about redefining the possibilities of treatments that could profoundly improve lives. With a focus on cutting-edge technology and an ambitious leadership team, they are positioned to make significant strides in the therapeutic landscape. As they tackle unmet medical needs, the potential for impact is vast—both in terms of revenue and, more importantly, human health.\n\nTo learn more, visit their website: [Abalone Bio](https://www.abalonebio.com)"
}